Bio-Rad Laboratories (BIO) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue reached $652M, up 2.1% year-over-year, with operating margin exceeding consensus due to strong execution and portfolio strength in a challenging macroeconomic environment.

• Life Science segment growth was led by process chromatography and food safety, while Clinical Diagnostics remained stable; Americas and EMEA led regional growth.

• Net income for Q2 2025 was $318M ($11.67/share), a turnaround from a net loss in Q2 2024, mainly due to gains in Sartorius AG equity holdings.

• Acquisition of Stilla Technologies closed, expanding the ddPCR portfolio and launching the QX700 Series and QX Continuum systems.

• Academic and biotech research markets remained soft, but consumables demand showed resilience and stabilization.

Financial highlights

• Q2 2025 net sales were $652M, up 2.1% year-over-year; Life Science revenue grew 4.9% to $263M, Clinical Diagnostics was flat at $389M.

• Q2 non-GAAP gross margin was 53.7% (down from 56.4% YoY); GAAP gross margin was 53.0%; operating margin was 13.6% non-GAAP and 11.8% GAAP.

• Non-GAAP net income was $71M ($2.61 EPS); reported net income was $318M ($11.67 EPS), including $250M+ from Sartorius AG equity.

• Free cash flow for Q2 was $71M, up from $55M YoY; H1 2025 free cash flow was $166.3M, up from $84.9M YoY.

• Share repurchases totaled $242.1M for 992,803 shares in H1 2025; $337M remains authorized.

Outlook and guidance

• 2025 currency-neutral revenue expected to be flat to 1% growth; Life Science outlook improved to flat to 1% growth, ddPCR portfolio revenue to grow mid-single digits.

• Diagnostics business growth narrowed to 0.5%-1.5%; full-year non-GAAP gross margin guided to 53.5%-54.5%, operating margin raised to 12%-13% (from 10%-12%).

• Free cash flow target for 2025 remains $310M-$330M.

• Management expects continued uncertainty in global economic and geopolitical conditions, with ongoing challenges in biopharma and small biotech markets.

• Liquidity and cash flow are considered sufficient for operational and strategic objectives.